Ensign Peak Advisors
ALGS icon

Ensign Peak Advisors’s Aligos Therapeutics ALGS Stock Holding History

Ensign Peak Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-293
Closed -$87K – 2208
2021
Q4 		$87K Buy
+293
New +$107K ﹤0.01% 2083

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ensign Peak Advisors's ALGS Position: Q1 2022 in Review

Ensign Peak Advisors sold out of Aligos Therapeutics (ALGS) in Q1 2022, closing a stake of 293 shares — an estimated $87K sold.

Ensign Peak Advisors first reported a position in ALGS in Q4 2021 and held it in 1 quarter. The position peaked at $87K in Q4 2021. 76 funds tracked by Wall St. Rank hold ALGS as of Q1 2022.

  • Ensign Peak Advisors reported no remaining Aligos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 293 Aligos Therapeutics shares in Q1 2022, an estimated $87K.
  • Ensign Peak Advisors first reported a position in Aligos Therapeutics in Q4 2021 and held it in 1 quarter.
  • Ensign Peak Advisors's Aligos Therapeutics position peaked at $87K in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2022.

Based on Ensign Peak Advisors's 13F filing for Q1 2022, filed 16 May 2022.